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1 |  INTRODUCTION
The CD40 ligand (CD40L) expressed by CD40LG fulfills 
diverse functions. T cell-expressed CD40L is involved in 
the stimulation of germinal center B cells, antibody isotype 
switching and the generation of high-affinity antibodies 
through the process called somatic hypermutation (SHM). 
Functional mutations in CD40LG result in a hyper-IgM syn-
drome characterized by normal to elevated IgM levels and 
low to absent IgG and IgA levels.
2 |  CASE PRESENTATION
A 12 months old male patient was referred to our university 
hospital due to a respiratory infection. Neutropenia, which 
subsequently lasted for 15 months (with neutrophil concen-
trations often <0.05 × 109/L (neutropenia grade 4), Figure 
1), was diagnosed. The patient was not thrombocytopenic 
and his erythrocytes were direct antiglobulin test (DAT) 
negative. Antinuclear antibodies (ANA) were not detected. 
He received subcutaneous granulocyte-colony stimulating 
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Abstract
This case suggests a mechanistic rationale for the clinical efficacy of intravenous 
immunoglobulins (IVIG) in treating CD40 ligand (CD40L) deficiency associated 
neutropenia as it is the first reported instance of free and cell-bound antineutrophil 
antibodies in a case of CD40L deficiency, accompanied by a prolonged and clinically 
severe neutropenia.
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factor (G-CSF), according to recommended dosage1 (5 μg/
kg/day  =  50  μg Neupogen®/day), for seven consecutive 
days, without effect on his neutrophil levels but for a 
marked increase in his eosinophil counts: 2.2 × 109/L (age-
adjusted range: <0.05  ×  109/L). A bone marrow biopsy 
showed lively erythropoiesis, normal thrombocytopoiesis, 
inhibited neutropoiesis, normal eosinophilopoiesis, and no 
signs of neoplastic hematologic disease. A possible celluli-
tis, located to his left instep, responded to amoxicillin and 
clavulanic acid. After discharge from the hospital, he was 
given preventive amoxicillin. In the following 10 months, 
his main complaints were gingivitis, oral ulcers, and mu-
cocutaneous candidiasis, the latter amenable to oral anti-
fungals. Next-generation sequencing, using a custom made 
in-house panel (Thermo Fischer Scientific) found no muta-
tions in genes associated with severe congenital neutrope-
nia: ELANE, HAX1, GFI1, WAS, or G6PC3 but revealed 
that the patient was hemizygous for two new genetic 
variants in CD40LG: LRG_141, c.[517G  >  C; 521delA] 
p.(Ala173Pro; Gln174fs). The patient's two CD40LG vari-
ants were confirmed by Sanger sequencing. None of the 
patient's CD40LG variants were described in the dbSNP da-
tabase at NCBI, nor in HGMD, nor in Exome Aggregation 
Consortium nor in 1000 Genomes Data. Three (SIFT, 
PolyPhen-2, and mutationassessor.org) out of six predic-
tion tools rated the missense variant c. 517G > C as proba-
bly damaging. The other deletion variant c. 521delA, which 
caused a frameshift at amino acid position 174 (Gln174fs) 
and introduced a stop codon at amino acid position 190, 
was clearly damaging. According to the sequence variant 
nomenclature: varnomen.hgvs.org, the two CD40LG vari-
ants are to be described as separate mutations.
The same CD40LG variants (in cis) were detected by 
Sanger sequencing in the patient's mother. The patient had 
F I G U R E  1  The patient's neutrophil 
concentrations during 28 mo (with 
15 mo of neutropenia) divided upon 38 
measurements. The blue line depicts the 
age-adjusted neutrophil concentration 
(lower normal range). G-CSF (50 μg/d) was 
administered daily for 7 d. Ten grams of 
intravenous Privigen® were administered 
every fourth week
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undetectable IgG (<0.4 g/L), IgA (<0.05 g/L) but elevated 
IgM (8.45 g/L) levels consistent with the hyper-IgM syn-
drome. A lymphocyte marker study, performed at the age 
of 27 months, showed normal CD4+, CD8+ T, and CD19+ 
B-cell concentrations but total absence (0%) of isotype 
switched (CD27+IgD−) memory B cells (age adjusted 5-95 
percentile range: 4.7%-21.2% of CD19+ B cells). Patient B 
cells exhibited reduced SHM (determined by a restriction 
enzyme-based hot spot mutation assay [REHMA]) of kappa 
light chain genes: 2% (age-adjusted normal range: >10%, 
Tissue Typing laboratory, National University Hospital, 
Copenhagen). Clostridium tetani antibody levels (follow-
ing three tetanus toxoid vaccinations) were nonprotective 
(<0.01 IU/mL, Statens Serum Institut). Ex vivo stimulation 
of his CD3+ T cells, with phorbol 12-myristate 13-acetate 
(PMA: 20  ng/mL) and ionomycin (300  ng/mL), failed to 
upregulate surface CD40L, although his CD3+ T cells were 
activated as evidenced by upregulation of surface CD69. 
Repeated testing of patient sera by the Luminex-based 
LABScreen multi-assay (prior to institution of antibody 
replacement therapy) revealed no antibody specificities 
toward a wide range of human leukocyte antigen (HLA)-
class I, HLA-class II determinants as well as toward human 
neutrophil antigens (HNAs). Patient sera (prior to and after 
institution of antibody replacement therapy) and patient 
neutrophils were tested for granulocyte-reactive antibod-
ies using flow direct-granulocyte immunofluorescence test 
(D-GIFT), flow indirect-granulocyte immunofluorescence 
test (I-GIFT), granulocyte agglutinations tests (GAT), and 
monoclonal-antibody-specific immobilization of granulo-
cyte antigens (MAIGA) as earlier described.2 Results were 
confirmed by another ISBT granulocyte immunology ref-
erence laboratory (Karolinska University Hospital). Patient 
neutrophils were repeatedly (moderately to heavily) cov-
ered with IgG (Figure 1) and the corresponding patient 
sera contained free neutrophil reactive (IgG) antibodies 
(Figure1). Possibly reflecting the aftermath of reactive 
leukocytosis (concomitant leukocyte: 20.5  ×  109/L (nor-
mal range <14.0 × 109/L) and lymphocyte concentration: 
13.8 × 109/L (normal range <7.9 × 109/L), but with nor-
mal CRP (<1 mg/L), we recorded a single instance where 
the patient's neutrophil concentration was normalized 
(≥1.6 × 109/L), (Figure 1) despite the presence of neutro-
phil auto-antibodies. The more prolonged normalization 
of our patient's neutrophil counts coincided with the dis-
appearance of free and cell-bound neutrophil antibodies 
(measured on three different occasions, Figure1). While 
on IVIG (10 g Privigen®/4th week was initiated at the age 
of 27 months, Figure 1) and prophylactic sulfamethoxaz-
ole with trimethoprim, our patient, aged three years and 
6  months, underwent successful allogeneic bone marrow 
transplantation. Written consent by the patient's parents and 
permission from the chairman of the Regional Committee 
on Health Research Ethics for Southern Denmark (case 
S-20192000-48) was obtained.
3 |  DISCUSSION
Neutropenia affects approximately two-thirds of patients with 
CD40L deficiency, leading to significant comorbidity due to 
mucocutaneous inflammation.3 The pathogenesis underlying 
CD40L deficiency associated neutropenia has not yet been 
clearly delineated. As bone marrow stromal cells express 
CD40,4 stimulation by CD40L can induce them to produce 
G-CSF.5 Hence, CD40L deficiency could compromise the 
ability of bone marrow stromal cells to secrete G-CSF, thereby 
causing neutropenia. Supporting that hypothesis, treatment 
with G-CSF has been reported to increase or normalize the neu-
trophil counts in CD40L deficiency.6 However, seven days of 
treatment with a standard dosage of G-CSF did not affect our 
patient's neutropenia but instead markedly increased his periph-
eral eosinophil concentration, indicating that the G-CSF levels 
were sufficient to induce myelopoietic lineage differentiation. 
Still, we cannot exclude that the standard G-CSF dosage was 
insufficient, since the patient, despite the presence of antineu-
trophil antibodies, experienced a pronounced, possibly reactive, 
neutrophil increase, consistent with G-CSF responsiveness. 
Infection-induced G-CSF secretion results in massive bone 
marrow neutrophil release7 which may override the effects of 
neutrophil antibodies. Hence, pronounced bone marrow release 
of neutrophils, secondary to infection, may have effected our 
patient's transiently normalized neutrophil count in the presence 
of neutrophil auto-antibodies. Theoretically, our patient could 
have experienced additional unrecorded instances of normal-
ized neutrophil concentrations, however, his prolonged clinical 
complaints, involving gingivitis, oral ulcers, and mucocutane-
ous candidiasis, indicated sustained neutropenia.
The clinical efficacy of IVIG, in treating CD40L defi-
ciency associated neutropenia,8 suggests that autoimmune 
mechanisms might also be involved, although autoimmune 
neutropenia has never been confirmed in this disorder8 and 
some authors even mention it as unlikely.9 We hereby repre-
sent the first case of CD40L deficiency, accompanied by un-
detectable plasma IgG and IgA concentrations, but where free 
and cell-bound antineutrophil IgG antibodies coincided with 
a protracted, clinically significant neutropenia. We were not 
able to determine the subclass specificity of these IgG anti-
bodies, but to varying degrees all IgG subclasses may engage 
Fc-receptors and thereby contribute to splenic opsonization of 
antibody-coated neutrophils. The mechanism (s) underlying 
our patient's sparse production of IgG is uncertain. However, 
CD40L independent production of IgG toward viral glyco-
proteins has been documented10 and neutrophils express 
several surface glycoproteins, such as CD11b11 and CD47,12 
which could constitute targets for CD40L independent IgG 
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production. Interestingly, Litinskiy et al13 have demonstrated 
that human dendritic cells can induce CD40L independent 
IgG class shift through expression of the B-cell stimulator 
proteins: B-cell activating factor of the tumor-necrosis-factor 
family (BAFF) and a proliferation-inducing ligand (APRIL). 
We were not able to confirm the antigen specificity of the 
IgG antibodies, however, we cannot preclude that the anti-
bodies were “neutrophil specific” as other autoantigen spec-
ificities were not detected (no thrombocytopenia, the patient 
was DAT negative and we observed no ANA reactivity). 
However, the lack of any known neutrophil antigen specific-
ity of these antibodies concurred with our patient's severely 
reduced SHM, as CD40L is crucial for SHM. Auto-reactivity 
is often a feature of compromised SHM, since inherently au-
to-reactive B-cell clones are prevented from rescuing them-
selves, through the process of SHM, from auto-reactivity, a 
process called “clonal redemption”.14
4 |  CONCLUSION
We present a case of CD40L deficiency where the presence 
of neutrophil reactive IgG coincided with a clinically severe 
neutropenia. Due to its diverse immunomodulatory capabili-
ties, IVIG therapy is widely used for treating autoimmune 
disorders. Our case suggests a mechanistic rationale for the 
clinical efficacy of IVIG in attenuating CD40L deficiency as-
sociated neutropenia and substantiates models showing that 
the requirement for CD40L, in mediating B-cell IgG isotype 
switching, can be circumvented.
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